The tax dispute between PT MI and the tax authorities highlights the complexity of the economic benefit test regarding royalty payments to overseas affiliates. The core of this case is the correction of royalty expenses amounting to Rp25.9 billion paid to MSP Japan, consisting of trademark and know-how royalties. The Respondent (DJP) argued that as a contract manufacturer, PT MI should not pay royalties for products resold to the brand owner, as it was deemed to provide no economic value-add to the local entity.
The conflict's crux lies in the interpretation of PT MI’s functional profile. The Respondent assessed PT MI as a "toll manufacturer" producing goods solely based on MSP's orders, making royalty payments for brand usage on products exported back to MSP appear unjustified. Conversely, PT MI asserted they are full-fledged manufacturers purchasing their own raw materials and utilizing technology licenses (know-how) and trademarks to ensure product quality meets global pharmaceutical standards (CPOB).
The Tax Court Bench took a highly technical middle ground in its legal considerations. Regarding know-how royalties, the Bench opined that production formulas and technology are crucial in the pharmaceutical industry to meet Good Manufacturing Practice (GMP) standards. Thus, the know-how was proven to provide tangible benefits in the production process, making the expense deductible. However, for trademark royalties, the Bench held that when products are sold back to the brand owner (MSP), the brand provides no additional commercial advantage to PT MI since the buyer is the licensor itself.
The implications of this ruling emphasize that in transfer pricing disputes, the mere existence of intangible property is insufficient; Taxpayers must prove the specific economic benefit received by the local entity. This decision serves as a vital precedent for manufacturing companies serving affiliate export markets to be more meticulous in separating royalty components between production technology and brand marketing. In conclusion, transfer pricing documentation strategies must clearly articulate the value distinction between technical manufacturing capabilities and a brand's market value.
A Comprehensive Analysis and the Tax Court Decision on This Dispute Are Available Here